D-0617-2026 Class II Ongoing

Recalled by Direct Rx — Dawsonville, GA

FDA drug recall D-0617-2026 was initiated by Direct Rx on Jun 22, 2026 and is designated Class II. Reason for recall: CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit The recall status is ongoing. Affected quantity: 263 Bottles.

Recall details

Product Type
Drugs
Report Date
Jul 1, 2026
Initiation Date
Jun 22, 2026
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
263 Bottles

Product description

DULOXETINE D/R, a) 30 mg (NDC 61919-482-30), 30 Caps; b) 30 mg (NDC 61919-482-60), 60 Caps; CYMBALTA, Packaged and Distributed by Direct Rx.

Reason for recall

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit

Distribution pattern

U.S. Nationwide

Code information

Lot: a) 09JA2530, 31JA2507, expires: 04/30/2027; b) Lot: 09DE2412, 09JA2528, 29JA2511, expires: 04/30/2027.

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0617-2026
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0617-2026. Report a data issue: hello@regdatalab.com.